Monopar Therapeutics Inc.MNPRNASDAQ
LOADING
|||
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | 49.70% |
| Q2 2025 | 5.27% |
| Q1 2025 | -83.44% |
| Q4 2024 | 908.31% |
| Q3 2024 | -12.97% |
| Q2 2024 | 17.07% |
| Q1 2024 | -6.71% |
| Q4 2023 | -21.34% |
| Q3 2023 | -17.44% |
| Q2 2023 | -3.55% |
| Q1 2023 | -21.38% |
| Q4 2022 | 21.40% |
| Q3 2022 | -16.66% |
| Q2 2022 | 23.87% |
| Q1 2022 | -15.37% |
| Q4 2021 | 8.50% |
| Q3 2021 | 23.77% |
| Q2 2021 | 22.34% |
| Q1 2021 | -26.07% |
| Q4 2020 | 29.97% |
| Q3 2020 | 50.86% |
| Q2 2020 | 141.72% |
| Q1 2020 | -41.00% |
| Q4 2019 | 165.54% |
| Q3 2019 | -33.24% |
| Q2 2019 | -60.59% |
| Q1 2019 | 60.39% |
| Q4 2018 | 71.55% |
| Q3 2018 | -38.36% |
| Q2 2018 | 7.77% |
| Q1 2018 | 47.79% |
| Q4 2017 | -97.89% |
| Q3 2017 | 4611.92% |
| Q2 2017 | 132.99% |
| Q1 2017 | 37.41% |
| Q4 2016 | 40.65% |
| Q3 2016 | 21.59% |
| Q2 2016 | -0.00% |
| Q1 2016 | 0.00% |